Partner Links
| Articles
| PAVE 100 HIV vaccine trial too risky in current state | | Date Added: September 23, 2008 08:28:21 PM |
| In the fall of 2007, research in the field of HIV vaccination was moving confidently towards larger trials involving a broader sweep of individuals. Two vaccines in particular stood at the forefront - the Merck STEP vaccine and the PAVE 100 - and the scientific community was generally optimistic about their potential. Both bore similarities in that they relied on an adenovirus type 5 (AD-5) as a delivery method, though at different points, and were believed to generate considerable immune responses. |
|
